DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 021520 S-031 S-032

SUPPLEMENT APPROVAL
RELEASE REMS REQUIREMENT

Eli Lilly and Company
Attention: Roland W. Usher, MS
Director, Global Regulatory Affairs, US
Lilly Corporate Center
Indianapolis, IN 46285

Dear Mr. Usher:

Please refer to your Supplemental New Drug Applications (sNDAs) dated and received March 15, 2011 (S-032) and March 16, 2011 (S-031), submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Symbyax (olanzapine and fluoxetine HCl) Capsules 3 mg/25 mg, 6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg, 12 mg/50 mg.

S-031

We acknowledge receipt of your amendment to S-031 dated May 31, 2011.

We also refer to our letter dated February 14, 2011, notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we believe should be included in the labeling for Symbyax (olanzapine and fluoxetine HCl) Capsules. This information pertains to patient survey results that showed that patients did not understand the most important safety risks associated with the use of Symbyax (olanzapine and fluoxetine HCl) Capsules.

This supplemental new drug application provides for revisions to the Medication Guide for Symbyax (olanzapine and fluoxetine HCl) Capsules, consistent with our letter dated February 14, 2011.

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

S-032

We acknowledge receipt of your risk evaluation and mitigation strategy (REMS) assessment dated September 17, 2010.

This supplemental new drug application proposes to eliminate the requirement for the approved risk evaluation and mitigation strategies (REMS) for Symbyax (olanzapine and fluoxetine HCl) Capsules.

We have completed our review of this supplemental application. It is approved, effective on the date of this letter.

RISK EVALUATION AND MITIGATION STRATEGY REQUIREMENTS

The REMS for Symbyax (olanzapine and fluoxetine HCl) Capsules were originally approved on March 19, 2009. The REMS consists of a Medication Guide and a timetable for submission of assessments of the REMS.

You propose that FDA no longer require a REMS for Symbyax (olanzapine and fluoxetine HCl) Capsules.

We have determined that maintaining the Medication Guide as part of the approved labeling is adequate to address the serious and significant public health concern and meets the standard in 21 CFR 208.1. Therefore, it is no longer necessary to include the Medication Guide as an element of the approved REMS to ensure that the benefits of Symbyax (olanzapine and fluoxetine HCl) Capsules outweigh its risks.

Therefore, we agree with your proposal and a REMS for Symbyax (olanzapine and fluoxetine HCl) Capsules is no longer required.

We remind you that the Medication Guide will continue to be part of the approved labeling in accordance with 21 CFR 208.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert, Medication Guide), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above or by fax to 301-847-8444.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact Keith Kiedrow, Pharm.D., Senior Regulatory Project Manager, at (301) 796-1924.

Sincerely,

{See appended electronic signature page}

Thomas Laughren, M.D.
Director
Division of Psychiatry Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

THOMAS P LAUGHREN
06/21/2011